Literature DB >> 6814714

[The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy].

W Herrmann, R Wyss, A Riondel, D Philibert, G Teutsch, E Sakiz, E E Baulieu.   

Abstract

RU-486 is a steroid which possesses a great affinity for the progesterone receptor, does not have a progesterone activity, but is indeed a strong antagonist of progesterone effects in animals. Oral administration induces the interruption of the luteal phase of the menstrual cycle and that of early pregnancy in women. Its mode of administration and its properties enable us to envisage a new methodology for menstrual cycle regulation and human birth control.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6814714

Source DB:  PubMed          Journal:  C R Seances Acad Sci III        ISSN： 0249-6313


  28 in total

Review 1.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.

Authors:  Kyoung-Jin Min; Ji Hoon Jang; Jung Tae Lee; Kyeong Sook Choi; Taeg Kyu Kwon
Journal:  J Mol Med (Berl)       Date:  2011-10-19       Impact factor: 4.599

3.  Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.

Authors:  L Klein-Hitpass; A C Cato; D Henderson; G U Ryffel
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

Review 4.  Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus.

Authors:  Margeaux Wetendorf; Francesco J DeMayo
Journal:  Int J Dev Biol       Date:  2014       Impact factor: 2.203

Review 5.  Contragestion by antiprogestin RU 486: a review.

Authors:  E E Baulieu; A Ulmann; D Philibert
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

6.  The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature.

Authors:  Hongyan Yuan; Geeta Upadhyay; Jin Lu; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2012-03-16

7.  Progesterone dependence and extratrophoblastic origin of pregnancy-associated plasma protein-A (PAPP-A) in early pregnancy.

Authors:  P Bischof; A M Schindler; R Wyss; W L Herrmann; P C Sizonenko
Journal:  Arch Gynecol       Date:  1986

8.  Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.

Authors:  H Michna; M R Schneider; Y Nishino; M F el Etreby
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

Review 9.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.

Authors:  R C Gaillard; A Riondel; A F Muller; W Herrmann; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.